|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Influenza vaccination in acute coronary syndromes patients in Thailand: the cost-effectiveness analysis of the prevention for cardiovascular events and pneumonia显示文摘BackgroundInfluenza 种痘临床上被显示了在急性冠的症候群(交流) 减少不利心血管的结果病人,而是经济观点能提供重要数据使决定明智。试图为心血管的事件和生长得很好的肺病 prevention.MethodsLifetime 费用,预期寿命,和调整质量的生活年( QALY )执行终生的年度流行性感冒种痘的经济评估的这研究在上的一个六健康的状态 Markov 模型条件的一个年周期长度以外被估计为交流的一个住院,中风,心失败,肺病,没有住院发生了,或死亡。40-year-old-and-above, 50-year-old-and-above,和 65-year-old-and-above 情形的三年龄组的比较被执行。增长划算比率(ICER ) 和网钱的利益(NMB ) 在 2016 表现为一个社会观点。模型坚韧性被单程、概率的敏感 analyses.ResultsThe 流行性感冒种痘决定在所有年龄组是划算的,由比泰国的可接受的 willingness-to-pay 阀值完全低的主导的 ICER (有更高的有效性的更低的费用)[ 160,000 THB ( 4,466.8 美金)每 QALY ],与 NMB 的大增长价值。特别,当大多数每年为每 patient.ConclusionsThe 在 129,092 THB (3,603.9 美金) 受益, 50-year-old-and-above 情形被显示出到在交流的标准处理的另外的流行性感冒种痘在所有年龄组是划算的,它应该在临床的实践和健康政策做过程被考虑。 | Apirak Sribhutom Arintaya Phrommintikul Wanwarang Wongcharoen Usa Chaikledkaew Suntara Eakanunkul Apichard Sukonthasam | 2018 | Journal of Geriatric Cardiology2018，15，6： | 9 |
| 2 | Management and risk factor control of coronary artery disease in elderly versus nonelderly: a multicenter registry显示文摘冠的动脉疾病(CAD ) 是死亡在的一个领先的原因老因为老化是动脉粥样硬化并且也的重要非可修改的风险因素差的结果的一个预言者。指导治疗可以贡献的指南的 Underuse 非最优的风险因素控制和更坏的结果在老。我们试图探索 CAD,风险因素控制以及目标成就的管理在与相比老 nonelderly CAD patients.MethodsThe 核心泰国是进行中的 multicenter,有在泰国的高动脉粥样硬化患者风险的病人的未来的、观察登记。在这个队注册的 4120 个 CAD 病人的数据被分析比较在之间老(年龄 65 年) 对 nonelderly (年龄 < 65 年).ResultsThere 是 2172 老并且 1948 nonelderly 病人。老 CAD 病人有高血压, dyslipidemia, atrial 纤维性颤动和长期的肾疾病的更高的流行。收到了冠的 revascularization 的病人的比例不是不同的在之间老并且 nonelderly CAD 病人。Antiplatelets 少些被规定在老当 statin 在类似的比例被规定时。除了血压目标的 glycemic 控制,低密度脂蛋白胆固醇,和吸烟停止的风险因素控制的目标成就在登记显示出的老 CAD patients.ConclusionsThe 核心泰国是更高的在 CAD 在之间的治疗的公平老、非老。除了血压目标,更高有的老 CAD 病人在风险因素控制目标成就评价。心血管的结果上的目标成就的效果将从进行中的队被表明。 | Arintaya Phrommimikul Rungroj Krittayaphong Wanwarang Wongcharoen Smonpom Boonyaratavej Chaiyasith Wongvipaporn Worapom Tiyanon Pakaphan Dinchuthai Rapeephon Kunjara-Na-Ayudhya Pyatat Tatsanavivat Piyamitr Sritara | 2016 | Journal of Geriatric Cardiology2016，13，12： | 4 |
| 3 | Electrocardiographic predictors of cardiovascular events in patients at high cardiovascular risk: a multicenter study显示文摘Background There are limited data on the prevalence of electrocardiographic (ECG) abnormalities, and their value for predicting a major adverse cardiovascular event (MACE) in patients at high cardiovascular risk. This study aimed to determine the prevalence of ECG abnormalities in patients at high risk for cardiovascular events, and to identify ECG abnormalities that significantly predict MACE. Methods Patients aged ≥ 45 years with established atherosclerotic disease (EAD) were consecutively enrolled from the outpatient clinics of the six participating hospitals during April 2011 to March 2014. The following data were collected: demographic data, cardiovascular risk factors, history of cardiovascular event, physical examination, ECG and medications. ECG was analyzed using Minnesota Code criteria. MACE included cardiovascular death, non-fatal myocardial infarction, and hospitalization due to unstable angina or heart failure. Results A total of 2009 patients were included, 1048 patients (52.2%) had established EAD, and 961 patients (47.8%) had multiple risk factors (MRF). ECG abnormalities included atrial fibrillation (6.7%), premature ventricular contraction (5.4%), pathological Q-wave (Q/QS)(21.3%), T-wave inversion (20.0%), intraventricular ventricular conduction delay (IVCD)(7.3%), left ventricular hypertrophy (LVH)(12.2%), and AV block (12.5%). MACE occurred in 88 patients (4.4%). Independent predictors of MACE were chronic kidney disease, EAD, and the presence of atrial fibrillation, Q/QS, IVCD or LVH by ECG. Conclusions A high prevalence of ECG abnormalities was found. The prevalence of ECG abnormalities was high even among those with risk factors without documented cardiovascular disease. | Rungroj Krittayaphong Muenpetch Muenkaew Polakit Chiewvit Nithima Ratanasit Yodying Kaolawanich Arintaya Phrommintikul | 2019 | Journal of Geriatric Cardiology2019，16，8： | 3 |
| 4 | PPARγ activator,rosiglitazone:Is it beneficial or harmful to the cardiovascular system?显示文摘Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor γ which is used to improve insulin resistance in patients with typeⅡdiabetes.Rosiglitazone exerts its glucose-lowering effects by improving insulin sensitivity.Data from various studies in the past decade suggest that the therapeutic effects of rosiglitazone reach far beyond its use as an insulin sensitizer since it also has other benefits on the cardiovascular system such as improvement of contractile dysfunction,inhibition of the inflammatory response by reducing neutrophil and macrophage accumulation,and the protection of myocardial injury during ischemic/reperfusion in different animal models.Previous clinical studies in typeⅡdiabetes patients demonstrated that rosiglitazone played an important role in protectingagainst arteriosclerosis by normalizing the metabolic disorders and reducing chronic inflammation of the vascular system.Despite these benefits,inconsistent findings have been reported,and growing evidence has demonstrated adverse effects of rosiglitazone on the cardiovascular system,including increased risk of acute myocardial infarction,heart failure and chronic heart failure.As a result,rosiglitazone has been recently withdrawn from EU countries.Nevertheless,the effect of rosiglitazone on ischemic heart disease has not yet been firmly established.Future prospective clinical trials designed for the specific purpose of establishing the cardiovascular benefit or risk of rosiglitazone would be the best way to resolve the uncertainties regarding the safety of rosiglitazone in patients with heart disease. | Siripong Palee Siriporn Chattipakorn Arintaya Phrommintikul Nipon Chattipakorn | 2011 | World Journal of Cardiology2011，3，5： | 3 |
| 5 | Rate of anticoagulant use, and factors associated with not prescribing anticoagulant in older Thai adults with non-valvular atrial fibrillation: A multicenter registry显示文摘Objectives To investigate the rate of anticoagulant use,the reasons for not prescribing anticoagulant,and the factors associated with non-prescription of anticoagulant in older Thai adults with non-valvular atrial fibrillation.Methods A multicenter registry of patients with non-valvular atrial fibrillation was conducted during 2014 to 2017 in Thailand.Demographic,medical history,antithrombotic medication,non-antithrombotic medication,and laboratory data were collected and analyzed.Data were compared between the older adult (≥ 65 years) and younger adult (< 65 years) groups.The reasons why anticoagulant was not prescribed were collected,and predictive factors were identified.Results A total of 3218 patients (1873 males) with an average age of 67.3 ± 11.3 years were included.Almost two-thirds (61.0%) of patients were in the older adult group.Anticoagulant was prescribed in 2422 patients (75.3%): 81.4% in the older adult group and 65.7% in the younger adult group.The three main reasons for not prescribing anticoagulant were already taking antiplatelets,patient refusal,and bleeding risk.These reasons were more common in older adults as compared to younger adults.Multivariate analysis revealed current use of antiplatelets to be the most important factor that predict the non-prescription of anticoagulant in older population.Conclusions The prevalence of anticoagulant prescription among older Thai adults with atrial fibrillation is 81.4%.Taking antiplatelet drugs was found to be the strongest reason that predicts the non-prescription of anticoagulant in this patient population.A guideline should be developed to optimize the use of anticoagulant and antiplatelet in older adults. | Rungroj Krittayaphong Arintaya Phrommintikul Pornchai Ngamjanyaporn Khanchai Siriwattana Wiwat Kanjanarutjawiwat Thoranis Chantrarat Roj Rojjarekampai Pontawee Kaewcomdee Patthrapon Sonkhammee | 2019 | Journal of Geriatric Cardiology2019，16，3： | 3 |
| 6 | Utility of Myocardial Fibrosis and Fatty Infiltration Detected by Cardiac Magnetic Resonance Imaging in the Diagnosis of Arrhythmogenic Right Ventricular Dysplasia—A Single Centre Experience显示文摘 | Heinz B. Pfluger Arintaya Phrommintikul Justin A. Mariani Joshi G. Cherayath Andrew J. Taylor | 2008 | Heart, Lung and Circulation2008，，： | 1 |
| 7 | Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis显示文摘 | Arintaya Phrommintikul Steven Joseph Haas Maros Elsik Henry Krum | 2007 | The Lancet2007，，9559： | 1 |
| 8 | QT Dispersion in HIV‐Infected Patients Receiving Combined Antiretroviral Therapy显示文摘 | Wanwarang Wongcharoen Somkhuan Suaklin Nualnit Tantisirivit Arintaya Phrommintikul Nipon Chattipakorn | 2014 | Ann Noninvasive Electrocardiol2014，，6： | 1 |
| 9 | The protective role of curcumin in cardiovascular diseases显示文摘 | Wanwarang Wongcharoen Arintaya Phrommintikul | 2009 | International Journal of Cardiology2009，，： | 1 |
| 10 | Prevalence of atrial fibrillation in Thai elderly显示文摘 | Arintaya Phrommintikul Pitsanuwat Detnuntarat Narawudt Prasertwitayakij Wanwarang Wongcharoen | 2016 | Journal of Geriatric Cardiology2016，13，3： | 1 |
| 11 | Evaluation of Diffuse Myocardial Fibrosis in Heart Failure With Cardiac Magnetic Resonance Contrast-Enhanced T 1 Mapping显示文摘 | Leah Iles Heinz Pfluger Arintaya Phrommintikul Joshi Cherayath Pelin Aksit Sandeep N. Gupta David M. Kaye Andrew J. Taylor | 2008 | Journal of the American College of Cardiology2008，，： | 1 |
| 12 | Acute oedema in the evaluation of microvascular reperfusion and myocardial salvage in reperfused myocardial infarction with cardiac magnetic resonance imaging显示文摘 | Arintaya Phrommintikul Hassan Abdel-Aty Jeanette Schulz-Menger Matthias G. Friedrich Andrew J. Taylor | 2009 | European Journal of Radiology2009，，3： | 1 |
| 13 | Safety and tolerability of intradermal influenza vaccination in patients with cardiovascular disease显示文摘BackgroundIt 是生长得很好的然而,那流行性感冒种痘与心血管的疾病(CVD ) 在病人减少不利心血管的结果在大多数国家的疫苗的范围率仍然保持低。特别地在收到 antithrombotic 治疗的 CVD 病人,关于肌内的注射的本地不利效果的担心是重要妨碍之一。这研究被进行估计安全,在 CVD patients.MethodsThis 疫苗的 intradermal 流行性感冒的副作用和 tolerability 是在由在5月16日 th 和5月30日 th , 2012 在 Maharaj Nakorn Chiang Mai 医院。病历,病人的可接受程度和不利效果用立即跟随种痘的病人并且由电话调查完成的一张写的问询表被收集八天 later.ResultsAmong 169 个病人, 52.1% 是女人和平均数变老是 63 ±12 年。冠的动脉疾病,瓣膜的心疾病和扩大心肌症在 121 是在场的(71.6%) , 40 (23.7%) 并且 8 (4.7%) 分别地。Antithrombotics 在 89.3% 被使用。在种痘以后,疼痛分数是 0, 1 或 2 (从 10 ) 在 44.4% , 15.1% ,和 27.6% 病人分别地。在种痘以后的八天,普通不利反应正在发痒 19 (11.9%) ,胀大 9 (5.7%) 并且疲劳(4.7%) 。没有 hematoma 或檫伤是 reported.ConclusionsThe intradermal 流行性感冒种痘是安全的并且很好在 CVD 病人与满足的高率容忍。这种技术应该在扩展流行性感冒疫苗范围是有用的。 | Arintaya Phrommintikul Wanwarang Wongcharoen Stun Kuanprasert Narawudt Prasertwitayakij Rungsrit Kanjanavanit Siriluck Gunaparn Apichard Sukonthasarn | 2014 | Journal of Geriatric Cardiology2014，11，2： | 0 |
| 14 | The rate of patients at high risk for cardiovascular disease with an optimal low-density cholesterol level: a multicenter study from Thailand显示文摘Background Hypercholesterolemia is a major risk factor for cardiovascular events in patients with established atherosclerotic disease (EAD) and in those with multiple risk factors (MRFs). This study aimed to investigate the rate of optimal low-density lipoprotein (LDL) cholesterol level in a multicenter registry of patients at high risk for cardiovascular events. Methods A multicenter registry of EAD and MRF patients was conducted. Demographic data,medical history,cardiovascular risk factors,anthropometric data,laboratory data,and medications were recorded and analyzed. We classified patients according to target LDL levels based on recommendation by the European Society of Cardiology (ESC) 2011 into Group 1 which is EAD and diabetes or chronic kidney disease (CKD)–target LDL below 70 mg/dL,and Group 2 which is MRF without diabetes or CKD–target LDL below 100 mg/dL. The rate of optimal LDL level in patients with Group 1 and Group 2 was analyzed and stratified according to the treatment pattern of lipid-lowering medications. Results A total of 3100 patients were included. Of those,51.7% were male. Average age was 65.8 ± 9.7 years. Average LDL level was 96.3 ± 32.6 mg/dL. A vast majority (92.7%) received statin and 9.3% received ezetimibe. Optimal LDL level was achieved in 20.3% of patients in Group 1 (LDL < 70 mg/dL),and in 46.6% in Group 2 (LDL < 100 mg/dL). The overall rate of optimal LDL control was 23% since 89.6% of study population belongs to Group 1. The rate of optimal LDL was not different between high and low potency statin. Factors that were associated with optimal LDL control were older age,the presence of coronary artery disease or peripheral artery disease. Conclusions The rates of optimal LDL level were unacceptably low in this study population. As such,a strategy to improve LDL control in high-risk population should be implemented. | Rungroj Krittayaphong Arintaya Phrommintikul Smonporn Boonyaratvej Rapeephon Kunjara Na Ayudhya Pyatat Tatsanavivat Chulaluk Komoltri Piyamitr Sritara | 2019 | Journal of Geriatric Cardiology2019，16，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员